|
19 Apr 2018 |
NovaDigm Therapeutics Announces Initiation of Phase 2a Clinical Trial of NDV-3A in Staphylococcus aureus
|
|
19 Apr 2018 |
Qu Biologics Begins Phase 2 Clinical Trial in Crohn’s Disease
|
|
18 Apr 2018 |
Elios Therapeutics Presents Initial Phase 2b Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the American Association for Cancer Research (AACR) 2018 Annual Meeting
|
|
17 Apr 2018 |
Merck Announces First Phase Three Studies for PCV-15 (V114) Its Investigational Pneumococcal Disease Vaccine
|
|
16 Apr 2018 |
Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors
|
|
15 Apr 2018 |
Emergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorisation of BioThrax in European Countries
|
|
15 Apr 2018 |
Personalized tumor vaccine shows promise in pilot trial
|
|
12 Apr 2018 |
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
|
|
05 Apr 2018 |
Vivaldi Biosciences Presents Data at the World Vaccine Congress Demonstrating Potential of deltaFLU as Universal Influenza Vaccine
|
|
02 Apr 2018 |
SELLAS Life Sciences Announces Positive Interim Data from Phase 2b NeuVax™ (nelipepimut-S) Clinical Trial in Combination with Herceptin® in HER2 1+/2+ Breast Cancer Patients
|
|
28 Mar 2018 |
Immunovaccine Announces Initiation of Patient Dosing in Investigator-Sponsored Phase 2 Clinical Trial of Its Lead Candidate DPX-Survivac Used in Combination with Pembrolizumab in Patients with DLBCL
|
|
27 Mar 2018 |
Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection
|
|
20 Mar 2018 |
AJ Vaccines successfully completes two phase III trials of its new low-dose IPV-Al vaccine
|
|
19 Mar 2018 |
SELLAS Life Sciences’ Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting
|
|
19 Mar 2018 |
Valneva Reports Positive Phase I Interim Results for Its Lyme Vaccine Candidate VLA15
|
|
16 Mar 2018 |
OSE Immunotherapeutics Receives Approval in Europe to Resume Patient Accrual for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
|
|
16 Mar 2018 |
TapImmune Announces Publication of Clinical Trial Results for the TPIV200 Cancer Vaccine in Clinical Cancer Research
|
|
14 Mar 2018 |
Inovio’s DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection
|
|
14 Mar 2018 |
Phase 1 clinical trial for Hantavirus vaccines yields positive interim results
|
|
13 Mar 2018 |
Valneva Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya
|
|
13 Mar 2018 |
Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program
|
|
08 Mar 2018 |
Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer
|
|
08 Mar 2018 |
VBL Therapeutics Announces Top-Line Results from Pivotal Phase 3 GLOBE Study in Patients with Recurrent Glioblastoma
|
|
05 Mar 2018 |
Aimmune Therapeutics Presents Results From the Positive, Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy at AAAAI-WAO
|
|
02 Mar 2018 |
AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs® PD01A and PD03A, Confirming Safety and Tolerability for Both Compounds as well as Immunogenicity for PD01A in Early MSA patients
|
